Psychiatric and Behavioural Side Effects Associated With Perampanel in Patients With Temporal Lobe Epilepsy. A Real-World Experience

被引:8
作者
Mammi, Anna [1 ,2 ]
Ferlazzo, Edoardo [1 ,2 ]
Gasparini, Sara [1 ,2 ]
Bova, Valentina [2 ]
Neri, Sabrina [1 ,2 ]
Labate, Angelo [3 ]
Mastroianni, Giovanni [1 ,2 ]
Bianco, Concetta Lo [1 ,2 ]
Cianci, Vittoria [2 ]
Aguglia, Umberto [1 ,2 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy
[2] Great Metropolitan Hosp BMM, Reg Epilepsy Ctr, Reggio Di Calabria, Italy
[3] Univ Messina, Dept BIOMORF, Neurol Unit, Messina, Italy
来源
FRONTIERS IN NEUROLOGY | 2022年 / 13卷
关键词
adverse effects; focal epilepsy; psychosis; irritability; anti-seizure medications; AMPA-RECEPTOR ANTAGONIST; RANDOMIZED PHASE-III; ADJUNCTIVE PERAMPANEL; ANTIEPILEPTIC DRUGS; ILAE COMMISSION; THERAPY; CLASSIFICATION; ADULTS;
D O I
10.3389/fneur.2022.839985
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Psychiatric and behavioural side effects are common, undesirable effects associated with antiseizure medication use. Temporal lobe epilepsy is the most common focal epilepsy in adults and it is frequently associated with drug resistance. Patients with intractable epilepsy are more likely to have psychiatric and behavioural side effects when taking antiseizure medications and seem to be at higher risk for psychiatric comorbidities. Perampanel is a novel anti-seizure medication approved for focal and generalised epilepsies as add-on therapy. This is a 12-week short-term observational prospective study on people with focal epilepsy consecutively recruited from an Italian tertiary epilepsy centre, aimed to compare incidence and severity of psychiatric and behavioural side effects associated with perampanel use in patients with temporal lobe epilepsy as compared to other focal epilepsies. All patients received add-on perampanel according to indication and clinical judgement. Incidence and severity of psychiatric and behavioural side effects were rated by Neuropsychiatric Inventory Questionnaire. All patients enrolled answered the questionnaire before starting perampanel and after 12 weeks of treatment. We found no significant difference in terms of incidence and severity of psychiatric and behavioural side effects associated with perampanel in patients with temporal lobe epilepsy as compared to other focal epilepsies. In line with the literature, the most common adverse effects were "irritability" for both groups and "aggression" for patients with other focal epilepsies.
引用
收藏
页数:5
相关论文
共 28 条
  • [1] Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy
    Chen, Baibing
    Choi, Hyunmi
    Hirsch, Lawrence J.
    Katz, Austen
    Legge, Alexander
    Buchsbaum, Richard
    Detyniecki, Kamil
    [J]. EPILEPSY & BEHAVIOR, 2017, 76 : 24 - 31
  • [2] The prevalence of psychosis in epilepsy; a systematic review and meta-analysis
    Clancy, Maurice J.
    Clarke, Mary C.
    Connor, Dearbhla J.
    Cannon, Mary
    Cotter, David R.
    [J]. BMC PSYCHIATRY, 2014, 14
  • [3] AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives
    Di Bonaventura, Carlo
    Labate, Angelo
    Maschio, Marta
    Meletti, Stefano
    Russo, Emilio
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (16) : 1751 - 1764
  • [4] Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy A Randomized Trial
    Engel, Jerome, Jr.
    McDermott, Michael P.
    Wiebe, Samuel
    Langfitt, John T.
    Stern, John M.
    Dewar, Sandra
    Sperling, Michael R.
    Gardiner, Irenita
    Erba, Giuseppe
    Fried, Itzhak
    Jacobs, Margaret
    Vinters, Harry V.
    Mintzer, Scott
    Kieburtz, Karl
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (09): : 922 - 930
  • [5] Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel
    Ettinger, Alan B.
    LoPresti, Antonia
    Yang, Haichen
    Williams, Betsy
    Zhou, Sharon
    Fain, Randi
    Laurenza, Antonio
    [J]. EPILEPSIA, 2015, 56 (08) : 1252 - 1263
  • [6] European Medicine Agency, 2021, FYC EPAR PROD INF
  • [7] Instruction manual for the ILAE 2017 operational classification of seizure types
    Fisher, Robert S.
    Cross, J. Helen
    D'Souza, Carol
    French, Jacqueline A.
    Haut, Sheryl R.
    Higurashi, Norimichi
    Hirsch, Edouard
    Jansen, Floor E.
    Lagae, Lieven
    Moshe, Solomon L.
    Peltola, Jukka
    Perez, Eliane Roulet
    Scheffer, Ingrid E.
    Schulze-Bonhage, Andreas
    Somerville, Ernest
    Sperling, Michael
    Yacubian, Elza Marcia
    Zuberi, Sameer M.
    [J]. EPILEPSIA, 2017, 58 (04) : 531 - 542
  • [8] Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305
    French, Jacqueline A.
    Krauss, Gregory L.
    Steinhoff, Bernhard J.
    Squillacote, David
    Yang, Haichen
    Kumar, Dinesh
    Laurenza, Antonio
    [J]. EPILEPSIA, 2013, 54 (01) : 117 - 125
  • [9] Adjunctive perampanel for refractory partial-onset seizures Randomized phase III study 304
    French, Jacqueline A.
    Krauss, Gregory L.
    Biton, Victor
    Squillacote, David
    Yang, Haichen
    Laurenza, Antonio
    Kumar, Dinesh
    Rogawski, Michael A.
    [J]. NEUROLOGY, 2012, 79 (06) : 589 - 596
  • [10] Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy
    Hanada, Takahisa
    Hashizume, Yutaka
    Tokuhara, Naoki
    Takenaka, Osamu
    Kohmura, Naohiro
    Ogasawara, Aichi
    Hatakeyama, Shinji
    Ohgoh, Makoto
    Ueno, Masataka
    Nishizawa, Yukio
    [J]. EPILEPSIA, 2011, 52 (07) : 1331 - 1340